Caribou Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

CRBU$0.41-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Licensing and other third-party revenue (including zero from a related party for each of the three- and six-month periods ended June 30, 2026, and $622 and $1,243 from a related party for the three and six months ended June 30, 2025, respectively)	$1,499	$2,667	$3,896	$5,020
Operating expenses:
Research and development	18,942	27,692	39,553	63,223
General and administrative	7,896	10,403	15,962	20,138
Impairment charges	—	12,150	—	12,150
Total operating expenses	26,838	50,245	55,515	95,511
Loss from operations	(25,339)	(47,578)	(51,619)	(90,491)
Other income (expense)
Impairment of equity investment	—	(9,158)	—	(9,158)
Other income, net	1,057	2,638	2,252	5,560
Total other income (expense)	1,057	(6,520)	2,252	(3,598)
Net loss	(24,282)	(54,098)	(49,367)	(94,089)
Other comprehensive loss
Net unrealized loss on available-for-sale marketable securities, net of tax	(48)	(127)	(174)	(215)
Net comprehensive loss	$(24,330)	$(54,225)	$(49,541)	$(94,304)
Net loss per share, basic and diluted	$(0.24)	$(0.58)	$(0.50)	$(1.01)
Weighted-average common shares outstanding, basic and diluted	100,985,698	93,028,698	98,437,862	92,855,060

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.